🔎 Trials Near Me

Home › Kanser sa Bato › Georgia

Pag-aaral pangklinika para sa Kanser sa Bato sa Georgia

6 pag-aaral para sa Kanser sa Bato ang naghahanap ng mga kalahok sa mga site sa Georgia.

Mga Lungsod sa Georgia

Opisyal na teksto ng pag-aaral (English)

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

  • Research Site, Atlanta
  • Research Site, Atlanta
  • Research Site, Newnan
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07011719

Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer

  • Tennessee Oncology, PLLC- Ringgold, Ringgold
Nagre-recruitPhase 1/2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 17, 2026 · NCT07227415

A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors

  • Research Site, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 31, 2026 · NCT05536141

Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma

  • Xencor Investigative Site, Atlanta
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT05433142

cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease

  • North Georgia Health System, Gainesville
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 pataas · Lahat ng kasarian · Na-update Ene 20, 2026 · NCT05366881

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Atlanta
  • Massive Bio SYNERGY-AI site, Savannah
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.